​

ACADIA Pharmaceuticals (ACAD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ACAD Stock Forecast

ACADIA Pharmaceuticals (ACAD) stock forecast, based on 31 Wall Street analysts, predicts a 12-month average price target of $20.00, with a high of $20.00 and a low of $20.00. This represents a 35.78% increase from the last price of $14.73.

$10 $15 $20 $25 $30 $35 High: $20 Avg: $20 Low: $20 Last Closed Price: $14.73

ACAD Stock Rating

ACADIA Pharmaceuticals stock's rating consensus is Buy, based on 31 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 20 Buy (64.52%), 10 Hold (32.26%), 1 Sell (3.23%), and 0 Strong Sell (0.00%).

Buy
Total 31 1 10 20 Strong Sell Sell Hold Buy Strong Buy

ACAD Price Target Upside V Benchmarks

TypeNameUpside
StockACADIA Pharmaceuticals35.78%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts--7
Avg Price Target--$24.86
Last Closing Price$14.73$14.73$14.73
Upside/Downside--68.77%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25667-120
Mar, 25667-120
Feb, 25666-119
Jan, 25676-120
Dec, 24676-120
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 03, 2025Yatin SunejaGuggenheim$20.00$18.498.17%35.78%
Aug 07, 2024Jeffrey HungMorgan Stanley$20.00$18.856.10%35.78%
Jun 26, 2024Keith TapperBMO Capital$31.00$15.50100.00%110.45%
May 09, 2024Andrew FeinH.C. Wainwright$27.00$17.1357.62%83.30%
May 09, 2024Joel BeattyRobert W. Baird$28.00$17.1363.46%90.09%
May 09, 2024Uy EarMizuho Securities$21.00$17.1322.59%42.57%
Apr 30, 2024Ashwani VermaUBS$27.00$17.1057.89%83.30%
Mar 12, 2024Ashwani VermaUBS$33.00$19.9865.17%124.03%
Mar 12, 2024Jay OlsonOppenheimer$19.00$19.98-4.90%28.99%
Mar 12, 2024Ami FadiaNeedham$32.00$19.9860.16%117.24%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 03, 2025GuggenheimBuyNeutraldowngrade
Oct 17, 2024GuggenheimBuyBuyhold
Oct 10, 2024UBSBuyBuyhold
Aug 07, 2024RBC CapitalEqual-WeightEqual-Weighthold
Aug 07, 2024Morgan StanleyOverweightEqual-Weightdowngrade
Jun 26, 2024BMO CapitalBuyOutperforminitialise
Jun 25, 2024RBC CapitalBuyBuyhold
May 09, 2024H.C. WainwrightBuyBuyhold
Apr 30, 2024RBC CapitalBuyBuyhold
Apr 30, 2024UBSBuyBuyhold

Financial Forecast

EPS Forecast

$-2 $-1 $0 $1 $2 $3 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.79$-1.05$-1.34$-0.37$1.37----
Avg Forecast$-1.84$-1.02$-1.32$-0.36$0.72$0.75$1.12$1.67$2.18
High Forecast$-1.70$-0.94$-1.25$-0.07$1.21$1.19$2.27$2.78$2.32
Low Forecast$-1.94$-1.08$-1.42$-0.47$0.43$0.24$0.43$0.11$2.07
Surprise %-2.72%2.94%1.52%2.78%90.28%----

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$441.75M$484.14M$517.24M$726.44M$957.80M----
Avg Forecast$443.75M$487.98M$514.79M$719.17M$969.65M$1.05B$1.17B$1.30B$1.44B
High Forecast$462.99M$509.14M$546.26M$723.91M$975.90M$1.09B$1.18B$1.31B$1.51B
Low Forecast$417.17M$458.75M$496.61M$709.72M$964.06M$1.02B$1.17B$1.29B$1.39B
Surprise %-0.45%-0.79%0.47%1.01%-1.22%----

Net Income Forecast

$-350M $-180M $-10M $160M $330M $500M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-281.58M$-167.87M$-215.97M$-61.29M$226.45M----
Avg Forecast$-257.72M$-187.72M$-252.14M$-61.29M$128.51M$134.26M$208.81M$282.56M$357.29M
High Forecast$-206.17M$-150.18M$-201.71M$-49.03M$197.58M$194.99M$371.62M$455.51M$379.72M
Low Forecast$-309.26M$-225.27M$-302.57M$-73.54M$70.93M$38.68M$71.02M$18.15M$339.05M
Surprise %9.26%-10.58%-14.34%-76.22%----

ACAD Forecast FAQ

Is ACADIA Pharmaceuticals stock a buy?

ACADIA Pharmaceuticals stock has a consensus rating of Buy, based on 31 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 20 Buy, 10 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that ACADIA Pharmaceuticals is a favorable investment for most analysts.

What is ACADIA Pharmaceuticals's price target?

ACADIA Pharmaceuticals's price target, set by 31 Wall Street analysts, averages $20 over the next 12 months. The price target range spans from $20 at the low end to $20 at the high end, suggesting a potential 35.78% change from the previous closing price of $14.73.

How does ACADIA Pharmaceuticals stock forecast compare to its benchmarks?

ACADIA Pharmaceuticals's stock forecast shows a 35.78% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and underperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for ACADIA Pharmaceuticals over the past three months?

  • April 2025: 30.00% Strong Buy, 30.00% Buy, 35.00% Hold, 0% Sell, 5.00% Strong Sell.
  • March 2025: 30.00% Strong Buy, 30.00% Buy, 35.00% Hold, 0% Sell, 5.00% Strong Sell.
  • February 2025: 31.58% Strong Buy, 31.58% Buy, 31.58% Hold, 0% Sell, 5.26% Strong Sell.

What is ACADIA Pharmaceuticals’s EPS forecast?

ACADIA Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $0.75, marking a -45.26% decrease from the reported $1.37 in 2024. Estimates for the following years are $1.12 in 2026, $1.67 in 2027, and $2.18 in 2028.

What is ACADIA Pharmaceuticals’s revenue forecast?

ACADIA Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $1.05B, reflecting a 10.06% increase from the reported $957.8M in 2024. The forecast for 2026 is $1.17B, followed by $1.3B for 2027, and $1.44B for 2028.

What is ACADIA Pharmaceuticals’s net income forecast?

ACADIA Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $134.26M, representing a -40.71% decrease from the reported $226.45M in 2024. Projections indicate $208.81M in 2026, $282.56M in 2027, and $357.29M in 2028.